Clinical Trials Directory

Trials / Completed

CompletedNCT05747963

Software-delivered CBT-I for Insomnia Disorder

A Prospective, Multicenter, Randomized Clinical Trial for Evaluating the Safety and Efficacy of Software-delivered Cognitive Behavioral Therapy for Insomnia in Patients With Insomnia Disorder.

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
236 (actual)
Sponsor
Peking University Sixth Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The goal of this prospective multicenter clinical trial is to evaluate the efficacy and safety of software-delivered cognitive behavioral therapy for insomnia (CBT-I) in Chinese patients with insomnia disorder (ID). The main questions it aims to answer are: (1) whether the software-delivered CBT-I is more effective than an online patient education (online-PE) at improving insomnia. (2) whether the software-delivered CBT-I is safe for treatment of insomnia symptoms. Participants will be randomized to receive (1) a software-delivered CBT-I using automated software called 'resleep' (one kind of digital device expected to treat insomnia targeted for Chinese patients); (2) online patient education (online-PE) about sleep. Researchers will compare the efficacy of a software-delivered CBT-I program and an online sleep education control at improving insomnia symptoms and other psychological outcomes.

Conditions

Interventions

TypeNameDescription
DEVICEsoftware-delivered CBT-IThe automated software called 'resleep' incorporates all core elements of CBT-I: sleep restriction, stimulus control, cognitive therapy, relaxation techniques, and sleep hygiene and education, tailoring content based on each participant's reported baseline sleep function and sleep progress. The 6-week treatment includes 42 times of intervention.
OTHERonline PESubjects in the control group will receive non-tailored information about insomnia and sleep health education content using the Wechat Official Account.

Timeline

Start date
2023-03-21
Primary completion
2024-03-21
Completion
2024-03-21
First posted
2023-02-28
Last updated
2024-08-06

Locations

5 sites across 1 country: China

Source: ClinicalTrials.gov record NCT05747963. Inclusion in this directory is not an endorsement.